Abstract
T cells that escaped immune regulation and subsequently target insulin-producing β-cells are thought to be a major contributor of type 1 diabetes (T1D) development (1). Thus, harnessing autoreactive effector T cells appears to be a central requirement for novel therapeutic approaches that are urgently needed. The studies by Lee et al. (2) and Penaranda et al. (3) in PNAS demonstrate that blockade of IL-7 signaling can revert recent onset diabetes by fostering the inhibitory programmed cell death 1 (PD-1) protein on diabetogenic T cells, thereby limiting their autoaggressive potential.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
